Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
-
Support Care Cancer · Feb 2004
Symptom control and palliative care content of abstracts presented at the Canadian Association of Radiation Oncologists annual meetings.
Half of all patients referred for radiotherapy are treated with palliative intent. Recent emphasis has been placed on the importance of symptom control and palliative care (SCPC) in the radiation oncology community. The purpose of this study was to determine the number of abstracts relating to SCPC presented at the annual Canadian Association of Radiation Oncologists (CARO) meetings, and whether this number has increased over time. ⋯ SCPC research is poorly represented at the annual CARO conferences. Research in this field should be promoted as the palliative patient population represents a large component of radiotherapy clinical practice. The recent emergence of dedicated palliative radiotherapy clinics should continue to increase palliative radiotherapy research.
-
Support Care Cancer · Jan 2004
ReviewWhat is wrong with the 30-year-old practice of scalp cooling for the prevention of chemotherapy-induced hair loss?
Since about 1970 scalp cooling has been used to prevent chemotherapy-induced hair loss, one of the most common and emotionally distressing side effects of cancer therapy. Generally accepted opinions, uncertainty and controversy, topics to study and recommendations for improving the results of scalp cooling are the subjects of this article which was also presented at the MASCC Symposium, June 2003, Berlin.
-
Support Care Cancer · Jan 2004
Randomized Controlled Trial Multicenter Study Clinical TrialMulticenter, randomized trial of ramosetron plus dexamethasone versus ramosetron alone in controlling cisplatin-induced emesis.
To establish whether the combination of a corticosteroid (dexamethasone) and the newer serotonin-3 (5-HT(3)) receptor antagonist ramosetron is superior to ramosetron alone in controlling cisplatin-induced emesis. ⋯ The antiemetic efficacy of ramosetron in cancer patients receiving highly emetogenic cisplatin chemotherapy is significantly enhanced by its use in combination with dexamethasone.
-
Support Care Cancer · Jan 2004
Clinical TrialEvaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade.
To evaluate the effectiveness and side effects of intrapericardial administration of cisplatin in prevention of recurrent malignant pericardial effusion. ⋯ Cisplatin administered directly into the pericardial space is a very effective and relatively safe method of treatment of recurrent malignant pericardial effusion, especially in the course of NSCLC.